-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...
More »SEARCH RESULT
What is novelty? -Rajshree Chandra
-The Indian Express The era of globalised markets is also an era of globalised sovereignties. Nation states must constantly sync their policies with global constituencies of policies and citizens. At times, domestic disharmony is the price nation states may be required and willing to pay. The case in point here is the proposed review of the intellectual property rights (IPR) policy, particularly those clauses that are related to pharmaceutical patent policy....
More »Cancer care goes free for the poor in Kerala -KPM Basheer
-The Hindu Business Line Through the ‘Sukrutham' scheme, the Kerala Government aims to take advanced cancer treatment to the poorest Kerala: "We have two options, medically and emotionally: give up or fight like hell," Lance Armstrong, champion cycle racer, who recovered from advanced testicular cancer once said about his battle against cancer. The American, fortunately, had the money to pay for the extremely expensive treatment. But, for the majority of 1.75 lakh...
More »Letter to PM about US-India Bilateral Relations on Intellectual Property
-Kafila.org Dear Prime Minister Modi ji, We, the undersigned, wish to share with you some of our concerns on India's position on intellectual property (IP), particularly in the context of bilateral relations between the United States of America and India. We gather from the US-India Joint Statement dated 30 September 2014 that the Indian Government (a)greeing on the need to foster innovation in a manner that promotes economic growth...
More »New hepatitis cure far too costly -Martin Khor
-Asia News Network A controversy is brewing over a new cure for hepatitis C because it is extremely expensive and patients in middle-income countries like Malaysia will find it way beyond their budget. There are an estimated 400,000 Malaysians with hepatitis C, but this is probably a significant under-estimate since many people are not aware that they have the virus. Worldwide, 170 million people live with the hepatitis C virus (HCV), and every...
More »